CLINICAL_TRIALS trial_result · 2025-12-17

Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease [Phase 3]

A Phase 3 trial evaluating the safety and tolerability of SAGE-718 in Huntington's disease was terminated, and results were posted on 2025-12-17.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Huntington's Disease | Phase 3 | Status: TERMINATED | Results posted: 2025-12-17